The invention relates to novel proteins with novel integrin and I domain activity and nucleic acids encoding these proteins. The invention further relates to the use of the novel proteins in the treatment of integrin related disorders. TABLE 1 Computationally designed mutants^a WT ido1q ido1r ido2r jlm2r Backbone Energy^b 1ido -1037  -1145 -1138 -1116  -678 1jlm -1059 +82758  -840 -1000 -1086 Position Residues 139 I — — V — 153 M — — A — 156 F L W — — 157 V — — I — 160 V I — — — 199 V I I I — 215 I L L — V 219 V — — — I 223 F — — — L 238 V F F I I 239 V L L L — 240 I L L — — 259 A L L — — 269 I L — — — 271 V F — — — 287 I V V V — 299 V A I I — 308 I V — — — ^aMutants are named according to the structure that was stabilized (ido or jlm), the solvation potential used (1 or 2) and the definition of core residues (q or r). ^bThe lowest energy rotamer configuration was calculated for each sequence in the lido structure, and cross-calculated in the ljlm structure, using both solvent potentials; all 50 core residues were used in order to make the q and r energies comparable. Results are shown for solvent potential 1 and were similar for potential 2. # A severe clash of the side-chain of F271 with the backbone caused the high energy of the 1q sequence in the 1jlm structure; no movement of the backbone is allowed by the design method.